Skip to content

International Delivery — £35 per Order

Home/Learn/PT-141
Back to Learn Hub
Peptide Guide

PT-141 (Bremelanotide)

Category: Melanocortin System

PT-141, also known as Bremelanotide, is a synthetic peptide that acts on the melanocortin receptor system. It was originally developed from Melanotan II and gained scientific attention because it works through central nervous system pathways rather than the vascular mechanisms used by traditional approaches. The FDA approved a commercial version under the brand name Vyleesi in 2019.

This guide compiles key literature themes, handling context, and practical comparison points for research-focused evaluation.

By Maylene · Page updated

Overview

The peptide is notable in pharmacology because it represents a fundamentally different mechanism for addressing sexual dysfunction. Instead of acting on blood flow, PT-141 activates melanocortin-4 (MC4R) receptors in the brain. This central mechanism was first discovered serendipitously during research into skin pigmentation.

Discovery & Background

PT-141 emerged from the Melanotan research program at the University of Arizona in the 1990s. Researchers Mac Hadley and Victor Hruby were developing Melanotan II for tanning when they noticed unexpected effects on sexual function in study participants. This led to the development of PT-141 as a derivative specifically optimized for MC4R activation. Palatin Technologies later developed it through clinical trials, and it received FDA approval in 2019.

Mechanism of Action

PT-141 activates melanocortin-4 receptors in the central nervous system, a pathway distinct from PDE5 inhibitors. This central mechanism affects arousal pathways at the neurological level.

  • 1
    Selectively activates melanocortin-4 (MC4R) receptors in the hypothalamus and limbic system
  • 2
    Works through central nervous system pathways, not vascular mechanisms
  • 3
    Stimulates dopaminergic activity in brain regions associated with arousal and motivation
  • 4
    May activate melanocortin-3 receptors (MC3R) to a lesser degree
  • 5
    Derived from alpha-MSH structure with modifications for receptor selectivity and stability
  • 6
    Effects are neurologically mediated, distinguishing it from peripheral vasodilators

Research Benefits

The benefit areas below reflect commonly discussed research interests for this peptide.

Central Mechanism

Acts through brain-based melanocortin pathways rather than peripheral vascular mechanisms, a fundamentally different pharmacological approach.

FDA-Approved Derivative

Bremelanotide received FDA approval in 2019, indicating it passed rigorous clinical safety and efficacy evaluation.

Novel Pharmacology

First-in-class melanocortin receptor agonist approved for this indication, opening new research avenues.

Melanocortin Research

Valuable research tool for studying the broader melanocortin receptor system and its role in behavior and metabolism.

Reported Side Effects & Considerations

  • •Nausea is the most common side effect (40% in clinical trials), usually mild and transient
  • •Flushing and headache reported in a subset of participants
  • •Transient increases in blood pressure observed (contraindicated in uncontrolled hypertension)
  • •May cause temporary skin darkening due to melanocortin activation

Storage Background: Freeze-Dried Vials

General background for lyophilised (freeze-dried) research peptides supplied as powder in vials. A prefilled pen is a different format: store it as its own label and product documentation state.

Temperature

2-8C refrigerated

Once Reconstituted

Use within 14 days when refrigerated

Shelf Life

24 months lyophilized at -20C

Frequently Asked Questions

What is PT-141?

PT-141 (Bremelanotide) is a synthetic peptide that activates melanocortin-4 receptors in the brain. It was developed from Melanotan II research and received FDA approval as Vyleesi in 2019.

How does PT-141 differ from PDE5 inhibitors?

PT-141 works through central nervous system melanocortin receptors in the brain, while PDE5 inhibitors work by increasing blood flow through peripheral vascular mechanisms. They have completely different pharmacological targets.

What is the melanocortin system?

The melanocortin system is a group of receptors (MC1R through MC5R) and their peptide ligands that regulate skin pigmentation, appetite, energy homeostasis, and other physiological processes.

How was PT-141 discovered?

It was discovered serendipitously during research into Melanotan II for skin tanning at the University of Arizona. Researchers noticed unexpected effects and developed PT-141 as a targeted derivative.

What are the main research applications?

PT-141 is primarily used in melanocortin receptor research, neurological arousal pathway studies, and as a pharmacological tool for understanding MC4R signaling.

Sources & evidence

Maylene research library

These papers describe the stated compounds and study models. They do not test or certify Maylene products. Animal or cell findings do not establish human benefit, and pharmaceutical trials do not validate research-only pens.

Editorial approach and corrections

Research Disclaimer

This guide is for educational and informational purposes only. All information is based on published scientific research and peer-reviewed literature. Peptides sold by Maylene are intended solely for laboratory research use and are not for human consumption. Consult healthcare professionals before making any health decisions.

The catalogue

There is no PT-141 product in the current catalogue. This guide is background reading.

Browse All Peptides

Explore More Peptide Guides

Explore adjacent compounds to compare mechanisms, side-effect discussions, and study focus across related peptides.

Start Your Research Today

Compare current listings, labelled content and product documentation before ordering.

Products from Maylene are supplied strictly for laboratory and scientific research use only.

Shop Peptides